ICI 182,780 penetrates brain and hypothalamic tissue and has functional effects in the brain after systemic dosing.
Previous reports suggest the antiestrogen ICI 182,780 (ICI) does not cross the blood-brain barrier (BBB). However, this hypothesis has never been directly tested. In the present study, we tested whether ICI crosses the BBB, penetrates into brain and hypothalamic tissues, and affects known neuroendocrine functions in ovariectomized rats. Using HPLC with mass spectrometry, ICI (1.0 mg/kg.d, 3 d) was detected in plasma and brain and hypothalamic tissues for up to 24 h with maximum concentrations of 43.1 ng/ml, and 31.6 and 38.8 ng/g, respectively. To evaluate antiestrogenic effects of ICI in the brain after systemic dosing, we tested its ability to block the effect of 17 alpha-ethinyl estradiol (EE) (0.3 mg/kg, 8 d) on tail-skin temperature abatement in the morphine-dependent model of hot flush and on body weight change. In the morphine-dependent model, EE abated 64% of the naloxone-induced tail-skin temperature increase. ICI pretreatment (1.0, 3.0 mg/kg.d) dose dependently inhibited this effect. ICI (3.0 mg/kg.d) alone showed estrogenic-like actions, abating 30% the naloxone-induced flush. In body weight studies, EE-treated rats weighed 58.5 g less than vehicle-treated rats after 8 d dosing. This effect was partially blocked by ICI (3.0 mg/kg.d) pretreatment. Similar to EE treatment, rats receiving 1.0 or 3.0 mg/kg.d ICI alone showed little weight gain compared with vehicle-treated controls. Thus, ICI crosses the BBB, penetrates into brain and hypothalamic tissues, and has both antiestrogenic and estrogenic-like actions on neuroendocrine-related functions.
Alfinito
Peter D
PD
Women's Health and Musculoskeletal Biology, Wyeth Research, RN 3164, 500 Arcola Road, Collegeville, Pennsylvania 19426, USA.
Chen
Xiaohong
X
Atherton
James
J
Cosmi
Scott
S
Deecher
Darlene C
DC
D000818:Animals; D001812:Blood-Brain Barrier / Q000378:metabolism*; D001835:Body Weight / Q000187:drug effects; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology; D004965:Estrogen Antagonists / Q000493:pharmacokinetics* / Q000494:pharmacology; D004997:Ethinyl Estradiol / Q000494:pharmacology; D005260:Female; D000077267:Fulvestrant; D019584:Hot Flashes / Q000139:chemically induced / Q000378:metabolism; D007031:Hypothalamus / Q000187:drug effects*; D009020:Morphine / Q000494:pharmacology; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D009294:Narcotics / Q000494:pharmacology; D010052:Ovariectomy; D051381:Rats; D017207:Rats, Sprague-Dawley; D012881:Skin Temperature / Q000187:drug effects; D014599:Uterus / Q000187:drug effects
D004965:Estrogen Antagonists; D009292:Narcotic Antagonists; D009294:Narcotics; D000077267:Fulvestrant; D009270:Naloxone; D004997:Ethinyl Estradiol; D004958:Estradiol; D009020:Morphine